“Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing”. 《Clinical Microbiology and Infection》 23 (4): 229–233. April 2017. doi:10.1016/j.cmi.2017.02.023. PMID28238870.
“Potential of old-generation antibiotics to address current need for new antibiotics”. 《Expert Review of Anti-Infective Therapy》 6 (5): 593–600. October 2008. doi:10.1586/14787210.6.5.593. PMID18847400.
“Detection of mcr-1 encoding plasmid-mediated colistin-resistant Escherichia coli isolates from human bloodstream infection and imported chicken meat, Denmark 2015”. 《Euro Surveillance》 20 (49): 30085. 2015년 12월 10일. doi:10.2807/1560-7917.ES.2015.20.49.30085. PMID26676364.
“Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa”. 《The Journal of Infectious Diseases》 202 (10): 1585–1592. November 2010. doi:10.1086/656788. PMID20942647.
“Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes”. 《Molecular Microbiology》 68 (1): 223–240. April 2008. doi:10.1111/j.1365-2958.2008.06152.x. PMID18312276.
“Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E”. 《The Journal of Antimicrobial Chemotherapy》 54 (1): 290–292. July 2004. doi:10.1093/jac/dkh289. PMID15190037.
“Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii”. 《The Journal of Infection》 53 (4): 274–278. October 2006. doi:10.1016/j.jinf.2005.11.019. PMID16442632.
“Is intraventricular colistin an effective and safe treatment for post-surgical ventriculitis in the intensive care unit?”. 《Acta Anaesthesiologica Scandinavica》 50 (10): 1309–1310. November 2006. doi:10.1111/j.1399-6576.2006.01126.x. PMID17067336.
“Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections”. 《The Lancet. Infectious Diseases》 6 (9): 589–601. September 2006. doi:10.1016/s1473-3099(06)70580-1. PMID16931410.
“Effects of blood pressure lowering in the acute phase of total anterior circulation infarcts and other stroke subtypes”. 《Cerebrovascular Diseases》 15 (4): 235–243. 2003. doi:10.1159/000069498. PMID12686786.
“In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii”. 《The Journal of Antimicrobial Chemotherapy》 41 (4): 494–495. April 1998. doi:10.1093/jac/41.4.494. PMID9598783.
“Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events”. 《Clinical Microbiology and Infection》 11 (8): 682–683. August 2005. doi:10.1111/j.1469-0691.2005.01198.x. PMID16008625.
“In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics”. 《Clinical Microbiology and Infection》 5 (1): 32–36. January 1999. doi:10.1111/j.1469-0691.1999.tb00095.x. PMID11856210.
“Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study”. 《The Lancet. Infectious Diseases》 16 (2): 161–168. February 2016. doi:10.1016/S1473-3099(15)00424-7. PMID26603172.
“Neurotoxic and nephrotoxic effects of colistin in patients with renal disease”. 《The New England Journal of Medicine》 266 (15): 759–762. April 1962. doi:10.1056/NEJM196204122661505. PMID14008070.
“Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy”. 《Annals of Internal Medicine》 72 (6): 857–868. June 1970. doi:10.7326/0003-4819-72-6-857. PMID5448745.
“Four years' experience of intravenous colomycin in an adult cystic fibrosis unit”. 《The European Respiratory Journal》 12 (3): 592–594. September 1998. doi:10.1183/09031936.98.12030592. PMID9762785.
“Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria”. 《International Journal of Antimicrobial Agents》 25 (1): 11–25. January 2005. doi:10.1016/j.ijantimicag.2004.10.001. PMID15620821.
“Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis”. 《The Annals of Pharmacotherapy》 34 (11): 1238–1242. November 2000. doi:10.1345/aph.19370. PMID11098334.
“Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers”. 《Journal of Cystic Fibrosis》 5 (4): 205–213. December 2006. doi:10.1016/j.jcf.2006.03.007. PMID16678502.
“Nebulized colistin causes chest tightness in adults with cystic fibrosis”. 《Respiratory Medicine》 88 (2): 145–147. February 1994. doi:10.1016/0954-6111(94)90028-0. PMID8146414.
“Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections”. 《The Lancet. Infectious Diseases》 6 (9): 589–601. September 2006. doi:10.1016/S1473-3099(06)70580-1. PMID16931410.
“Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate”. 《The Journal of Antimicrobial Chemotherapy》 53 (5): 837–840. May 2004. doi:10.1093/jac/dkh167. PMID15044428.
“Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections”. 《Clinical Infectious Diseases》 40 (9): 1333–1341. May 2005. doi:10.1086/429323. PMID15825037.
“Colomycin Injection”. 《Summary of Product Characteristics》. electronic Medicines Compendium (eMC). 2016년 5월 18일. 2017년 7월 16일에 원본 문서에서 보존된 문서. 2017년 6월 3일에 확인함.
“Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing”. 《Clinical Microbiology and Infection》 23 (4): 229–233. April 2017. doi:10.1016/j.cmi.2017.02.023. PMID28238870.
“Potential of old-generation antibiotics to address current need for new antibiotics”. 《Expert Review of Anti-Infective Therapy》 6 (5): 593–600. October 2008. doi:10.1586/14787210.6.5.593. PMID18847400.
“Detection of mcr-1 encoding plasmid-mediated colistin-resistant Escherichia coli isolates from human bloodstream infection and imported chicken meat, Denmark 2015”. 《Euro Surveillance》 20 (49): 30085. 2015년 12월 10일. doi:10.2807/1560-7917.ES.2015.20.49.30085. PMID26676364.
“Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa”. 《The Journal of Infectious Diseases》 202 (10): 1585–1592. November 2010. doi:10.1086/656788. PMID20942647.
“Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes”. 《Molecular Microbiology》 68 (1): 223–240. April 2008. doi:10.1111/j.1365-2958.2008.06152.x. PMID18312276.
“Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E”. 《The Journal of Antimicrobial Chemotherapy》 54 (1): 290–292. July 2004. doi:10.1093/jac/dkh289. PMID15190037.
“Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii”. 《The Journal of Infection》 53 (4): 274–278. October 2006. doi:10.1016/j.jinf.2005.11.019. PMID16442632.
“Is intraventricular colistin an effective and safe treatment for post-surgical ventriculitis in the intensive care unit?”. 《Acta Anaesthesiologica Scandinavica》 50 (10): 1309–1310. November 2006. doi:10.1111/j.1399-6576.2006.01126.x. PMID17067336.
“Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections”. 《The Lancet. Infectious Diseases》 6 (9): 589–601. September 2006. doi:10.1016/s1473-3099(06)70580-1. PMID16931410.
“Effects of blood pressure lowering in the acute phase of total anterior circulation infarcts and other stroke subtypes”. 《Cerebrovascular Diseases》 15 (4): 235–243. 2003. doi:10.1159/000069498. PMID12686786.
“In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii”. 《The Journal of Antimicrobial Chemotherapy》 41 (4): 494–495. April 1998. doi:10.1093/jac/41.4.494. PMID9598783.
“Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events”. 《Clinical Microbiology and Infection》 11 (8): 682–683. August 2005. doi:10.1111/j.1469-0691.2005.01198.x. PMID16008625.
“In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics”. 《Clinical Microbiology and Infection》 5 (1): 32–36. January 1999. doi:10.1111/j.1469-0691.1999.tb00095.x. PMID11856210.
“Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study”. 《The Lancet. Infectious Diseases》 16 (2): 161–168. February 2016. doi:10.1016/S1473-3099(15)00424-7. PMID26603172.
“Neurotoxic and nephrotoxic effects of colistin in patients with renal disease”. 《The New England Journal of Medicine》 266 (15): 759–762. April 1962. doi:10.1056/NEJM196204122661505. PMID14008070.
“Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy”. 《Annals of Internal Medicine》 72 (6): 857–868. June 1970. doi:10.7326/0003-4819-72-6-857. PMID5448745.
“Four years' experience of intravenous colomycin in an adult cystic fibrosis unit”. 《The European Respiratory Journal》 12 (3): 592–594. September 1998. doi:10.1183/09031936.98.12030592. PMID9762785.
“Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria”. 《International Journal of Antimicrobial Agents》 25 (1): 11–25. January 2005. doi:10.1016/j.ijantimicag.2004.10.001. PMID15620821.
“Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis”. 《The Annals of Pharmacotherapy》 34 (11): 1238–1242. November 2000. doi:10.1345/aph.19370. PMID11098334.
“Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers”. 《Journal of Cystic Fibrosis》 5 (4): 205–213. December 2006. doi:10.1016/j.jcf.2006.03.007. PMID16678502.
“Nebulized colistin causes chest tightness in adults with cystic fibrosis”. 《Respiratory Medicine》 88 (2): 145–147. February 1994. doi:10.1016/0954-6111(94)90028-0. PMID8146414.
“Induced tolerance to nebulized colistin after severe reaction to the drug”. 《Journal of Investigational Allergology & Clinical Immunology》 17 (1): 59–61. 2007. PMID17323867.
“Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections”. 《The Lancet. Infectious Diseases》 6 (9): 589–601. September 2006. doi:10.1016/S1473-3099(06)70580-1. PMID16931410.
“Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate”. 《The Journal of Antimicrobial Chemotherapy》 53 (5): 837–840. May 2004. doi:10.1093/jac/dkh167. PMID15044428.
“Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections”. 《Clinical Infectious Diseases》 40 (9): 1333–1341. May 2005. doi:10.1086/429323. PMID15825037.
“Colomycin Injection”. 《Summary of Product Characteristics》. electronic Medicines Compendium (eMC). 2016년 5월 18일. 2017년 7월 16일에 원본 문서에서 보존된 문서. 2017년 6월 3일에 확인함.
